Thailand
to cease Sinovac vaccine use when stocks end this month
Send a link to a friend
[October 18, 2021]
BANGKOK (Reuters) - Thailand will stop
using the COVID-19 vaccine of China's Sinovac when its current stock
finishes, a senior official said on Monday, having used the shot
extensively in combination with Western-developed vaccines.
|
Thailand used over 31.5 million Sinovac doses since February,
starting with two doses to frontline workers, high-risk groups and
residents of Phuket, a holiday island that reopened to tourists
early in a pilot scheme.
In July, Thailand started inoculating https://www.reuters.com/world/asia-pacific/thailand-starts-tighter-coronavirus-lockdown-around-capital-2021-07-12
people with Sinovac as a first dose followed by the Oxford
University-developed AstraZeneca. Thailand was the first country to
combine a Chinese and Western shots, a strategy its health officials
said has proved effective.
"We expect to have distributed all Sinovac doses this week," said
health official Opas Karnkawinpong, adding the programme will switch
to combining the AstraZeneca vaccine with that made by Pfizer and
BioNTech .
Thailand next year plans to buy 120 million COVID-19 vaccine doses
in total and has already booked 60 million doses of AstraZeneca, a
vaccine it manufactures locally.
Thailand has said it will only procure vaccines effective against
new variants.
[to top of second column] |
It has so far vaccinated 36% of
the estimated 72 million people who live in
Thailand and hopes to reach 70% by year-end.
The country is forging ahead with a
quarantine-free reopening plan next month of 17
provinces to vaccinated arrivals from low risk
countries. Included will be destinations like
Pattaya, Hua Hin, Chiang Mai and Bangkok.
Thailand has recorded nearly 1.8 million cases
and 18,336 fatalities overall, more than 98% in
the past seven months.
(Reporting by Chayut Setboonsarng and Panarat
Thepgumpanat; Editing by Martin Petty)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |